The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer
Open accessAbstract
Plasma membrane macromolecular complexes function as signaling hubs that regulate cell behavior, which is particularly relevant in cancer. Our study provides evidence that the complex formed by the hERG1 potassium channel and the β1 subunit of integrin receptors preferentially localizes in Lipid Rafts (LRs) in Pancreatic Ductal Adenocarcinoma (PDAC) cell lines and primary samples. The complex recruits the p85 subunit of phosphatidyl-inositol-3-kinase (PI3K), activating phosphoinositide metabolism and triggering an intracellular signaling pathway centered on Akt. This pathway ultimately affects cancer cell proliferation through cyclins and p21, and cell migration through the small GTPase Rac-1 and f-actin organization. The hERG1/β1 integrin complex in LRs can be dissociated and the downstream signaling pathway can be inhibited by either disrupting LRs through methyl-beta-cyclodextrin (MβCD) or inhibiting cholesterol synthesis by statins. Treatment with a single chain bispecific antibody—scDb-hERG1-β1—specifically targeting the complex significantly potentiates the effects of both MβCD and statins on intracellular signaling. Consequently, these treatments decrease PDAC cell proliferation and motility in vitro. From a pharmacological perspective, different statins produce anti-neoplastic effects in synergy with scDb-hERG1-β1. Such combination also enhances tumor sensitivity to chemotherapeutic drugs, such as gemcitabine and oxaliplatin. The efficacy of these combination treatments depends on the amount of the hERG1/β1 integrin complex present on the plasma membrane of cancer cells. Finally, the combined treatment with statins and scDb-hERG1-β1 significantly reduces tumor growth and improves survival in vivo, in a preclinical mouse model. These results suggest that the combination of scDb-hERG1-β1 and statins represent a potential novel strategy for treating PDAC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Effects of MβCD and scDb-hERG1-β1 treatment on hERG1/β1 integrin complex in PDAC cells after cell adhesion on Fibronectin. A Flow cytometry plots of hERG1 expression onto the plasma membrane in HEK-HERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD for 20 min [48]. Values are expressed as mean fluorescence intensity of the area under the curve (MFI). Representative plots are on the left, while quantitative analyses are reported in the graphs on the right. a.u. = arbitrary units Data are mean values ± s.e.m. obtained from three independent experiments (n = 3). B Co-IP between hERG1 and β1 integrin on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with and without treatment with 5 mM MβCD and corresponding densitometric analysis. Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed too. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. The WBs relative to the inputs are in figure and in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. C IF performed on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of scDb-hERG1-β1 staining is on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. D HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of caveolin-1 staining and colocalization between scDb-hERG1-β1 and caveolin-1 are on the left, while quantitative analyses (fluorescent intensity and Mander’s Overlapping Coefficient, MOC) are reported in the graphs on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. E IF performed on PANC-1 cells following 90 min adhesion onto FN with or without treatment with scDb-hERG1-β1 (20 μg/ml). Representative images of colocalization between scDb-hERG1-β1 and caveolin-1 (scale bar: 100 μm) are on the left, while quantitative analyses (MOC) are reported in the graph on the right. a.u. = arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. F Co-IP between hERG1 and PI3K p85 in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20ug/ml), and their combination, seeded on FN for 90 min. Total cell proteins were immunoprecipitated with anti-hERG1 mAb. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. Total lysates indicated as “inputs” are reported in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. G IF performed on PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml), and their combination, seeded on FN for 90 min. Representative images of PIP2 (top panels) and PIP3 (bottom panels) (scale bar: 50 μm) are on the top, while quantitative analyses (Mean fluorescence intensity) are reported in the graph on the bottom. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. Lower magnification images are reported in Supplementary Fig. 3. H Representative blot (left) and densitometric analysis (right) of ERK and phospho-ERK levels in PANC-1 cells untreated (CTR) or treated with scDb-hERG1-β1 (20 µg/ml), MβCD (5 mM) and their combination, seeded on FN for 90 min and a negative control, labeled BSA. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-pAkt Thr308, anti-Akt Thr308, ERK1/2 (pERK1/2) (Thr202/tyr204) and anti-total ERK1/2 antibodies. CTR control, MβCD Methyl-β-cyclodextrin, MOC Mander’s Overlapping Coefficient, IP immunoprecipitation, BSA bovine serum albumin. All data are presented as mean values ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA).](https://figures.cochat.ai/paper-figures/500e2444bacd44488792ae44a489d21d/targeting-the-herg1-1-integrin-complex-in-lipid-rafts-potentiates-statins-anti-figure-3.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Duranti et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The treatment of the PDAC cell lines with statins: simvastatin, lovastatin, fluvastatin, atorvastatin disrupted the lipid rafts and the hERG1/β1 complex by reducing intracellular cholesterol, also significantly reducing cell viability in 24 h after treatment.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Duranti et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was determined that a complex formed of the hERG1 potassium channel and β1 integrin is preferentially local in the cell membrane lipid rafts (Duranti et al., 2025).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Duranti et al., 2025
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Further, the effect of the combination of statins with gemcitabine and oxaliplatin was tested on cell lines, where they showed a synergistic effect (Duranti et al., 2025).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Duranti et al., 2025
The cited source says what the claim attributes to it.
In the citing paper
“The disruption of hERG1/β1 complex or lipid rafts by the bispecific antibody scDb-hERG1-β1 antibody and methyl-β-cyclodextrin (MβCD), respectively, in PDAC cell lines, decreases cell signaling by mechanisms such as reduction of the p85 subunit of phosphoinositide 3-kinase (PI3K), decreasing levels of phosphatidylinositol-3,4,5-triphosphate (PIP3), increasing phosphatidylinositol-4,5-bisphosphate (”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Duranti et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional rafts in cell membranes
Simons, K., & Ikonen, E. (1997) · Nature · doi:10.1038/42408 · Cited by 9,757
Gürsoy, G., Xu, Y., & Liang, J. (2014) · States at War, Volume 3 · doi:10.14440/jbm.2018.259.s1024 · Cited by 8,771
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371 · cited 1×
“Lipid rafts (LRs) are major membrane organizers of spatially restricted cellular signals [6].”
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
The mystery of membrane organization: composition, regulation and roles of lipid rafts
Sezgin, E., Levental, I., Mayor, S., & Eggeling, C. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.16 · Cited by 2,124 · cited 1×
“Such molecular composition determines the high lateral fl uidity and the constant assembly/disassembly dynamics of LRs [8].”
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 1×
“Since Akt can affect cell cycle progression through a complex array of signaling molecules which converge to the modulation of cyclins [53], we then determined the effects of M β CD, the scDb- hERG1-β 1 or both on signaling molecules regulating cell cycle progression on PDAC cells on FN at T 90 .”
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027 · cited 1×
“We addressed these aims in Pancreatic Ductal Adeno Carcinoma (PDAC) which still represents an unmet medical need [42] where novel therapeutic interventions are expected.”
Cooper, J., & Giancotti, F. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.007 · Cited by 945 · cited 1×
“We then analyzed the effects of either treatment on the signaling pathways downstream to PI3K which are commonly triggered by integrins in cancer cells [50], focusing on Akt and the small GTPase Rac-1, which we already showed to be preferentially activated down-stream to hERG1 [36].”
Bilayer Thickness and Membrane Protein Function: An Energetic Perspective
Andersen, O. S., & Koeppe, R. E. (2007) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.36.040306.132643 · Cited by 866 · cited 1×
“In brief, (i) speci fi c lipids can directly affect ion channel functionality, e.g., in voltage-dependent K + channels (K V ) [27 – 30], or (ii) LRs concentrate protein kinases that modulate K V activity, such as the Src kinase [24], often through the intervention of caveolin-1 [31].”
Cell motility in cancer invasion and metastasis: insights from simple model organisms
Stuelten, C. H., Parent, C. A., & Montell, D. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.15 · Cited by 519 · cited 1×
“…complexes often comprise growth factor receptors [3] as well as ion channels and transporters [4] and thereby regulate signaling pathways whose derangement is critical in the pathophysiology of cancer, such as those implicated in cell proliferation, survival, motility and invasiveness [5].”
Cited by
Karthikeyan, S., Somasundaram, P., Karimi, I., Lagunas‐Rangel, F. A., Alsehli, A. M., Fredriksson, R., Jonsson, J., & Schiöth, H. B. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107912 · Cited by 24
“For example, statins may affect the process, wherein the hERG1 potassium channel in LRs recruits PI3K via its β 1 integrin-binding domain, forming a cholesterol-dependent complex that activates Akt to regulate cancer cell motility and proliferation [121].”
Targeting ion channel dysregulation in tumors: emerging therapeutic opportunities
Liu, W. L., Xie, X., Chen, H., Wan, Y., Tang, B., & Mao, W. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.11.010 · Cited by 7
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
InfluentialNguyễn, P., & Stary-Weinzinger, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1905919
“…targeting the hERG1/ β 1-integrin complex produces a synergistic inhibitory effect on tumor growth, which demonstrate that lipid rafts are essential for the oncogenic signaling functions of hERG1 and highlight their potential as therapeutic targets in pancreatic cancer (Duranti et al., 2025).”
Potassium channels in cancer: from hallmarks to therapeutic targeting
Zhang, Y.-L., Shi, R.-J., & Liang, X. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01228-5
Metadata
- Authors
- Duranti, C., Iorio, J., Manganelli, V., Bagni, G., Colasurdo, R., Lottini, T., Martinelli, M., Capitani, C., Boso, G., D’Alessandro, F. N., Sorice, M., Becchetti, A., Misasi, R., Garofalo, T., & Arcangeli, A.
- Affiliations
- University of Florence (IT)
- Sapienza University of Rome (IT)
- University of Siena (IT)
- University of Milano-Bicocca (IT)
- Corresponding author
- Arcangeli, Annarosa
- ORCID
- Venue
- Cell Death Discovery
- Published
- 2025-02-03
- Volume
- 11
- Issue
- 1
- Pages
- 39-39
- ISSN
- 2058-7716 (ISSN-L)
- PMC
- PMC11790905
- OpenAlex
- W4407104486
- Cited by
- 8
- References
- 81
- Citations by year
- 2026: 6 · 2025: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death Discovery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Università degli Studi di Firenze (ex 60%)
- Associazione Italiana per la Ricerca sul Cancro (1662, 15627, 21510)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- hERG1, beta1 integrin, lipid rafts, pancreatic ductal adenocarcinoma, statins, PI3K/Akt signaling, phosphoinositide metabolism, bispecific antibodies, methyl-β-cyclodextrin, cholesterol biosynthesis, cell proliferation, cell migration, Rac1, gemcitabine, oxaliplatin, combination therapy, tumor growth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41420-025-02321-2
- The paper
- Duranti, C., Iorio, J., Manganelli, V., Bagni, G., Colasurdo, R., Lottini, T., Martinelli, M., Capitani, C., Boso, G., D’Alessandro, F. N., Sorice, M., Becchetti, A., Misasi, R., Garofalo, T., & Arcangeli, A. (2025). Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-025-02321-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.